Advertisement
New Zealand markets close in 2 hours

  • NZX 50

    11,756.73
    -79.31 (-0.67%)
     

  • NZD/USD

    0.5864
    -0.0042 (-0.71%)
     

  • NZD/EUR

    0.5519
    -0.0025 (-0.46%)
     

  • ALL ORDS

    7,772.20
    -126.70 (-1.60%)
     

  • ASX 200

    7,522.00
    -120.10 (-1.57%)
     

  • OIL

    86.10
    +3.37 (+4.07%)
     

  • GOLD

    2,423.00
    +25.00 (+1.04%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,129.29
    -256.58 (-1.57%)
     

  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

  • NZD/JPY

    90.2470
    -1.0070 (-1.10%)
     

MacroGenics to Participate in Upcoming Investor Conference

MacroGenics, Inc.
·1-min read
MacroGenics, Inc.
MacroGenics, Inc.

ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in May 2022.

  • H.C. Wainwright Global Investment Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate overview in Miami, FL, on Wednesday, May 25, 2022, at 11:30 am ET. Management will also participate in one-on-one meetings.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.

ADVERTISEMENT

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. 

CONTACT: CONTACTS: Chris James, M.D., Vice President, Investor Relations & Corporate Communications Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com